Ainda em busca do ensaio ideal para a tiroglobulina sérica no seguimento de pacientes com câncer diferenciado da tiróide

Maciel, Rui M. B.

doi:10.1590/s0004-27302004000400001

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polyclonal and monoclonal antibodies used in immunoassays recognize Tg epitopes present in the immunization preparation used to generate them, and these forms may not be predominant in a serum sample. Recent studies have shown that available assays may differ significantly in the levels of Tg detected (8,9), and the search for the ideal assay is still a challenge (10).…”

Section: Introductionmentioning

confidence: 99%

Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin

Nakabashi

Biscolla

Kasamatsu

et al. 2012

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

OBJECTIVE: In the last decade, data published stressed the role of highly-sensitive thyroglobulin (Tg) assays in the follow-up of differentiated thyroid carcinoma (DTC) patients. The present study describes a new, highly-sensitive Tg assay, compares it with an available commercial assay, and validates it in the follow-up of DTC patients. SUBJECTS AND METHODS: The immunofluorometric high-sensitivity Tg assay is based on monoclonal and polyclonal antibodies produced at our laboratories. It was validated in 100 samples of 87 patients with DTC submitted to total thyroidectomy, 87% of whom also received radioiodine. For correlation, all samples were also tested using a commercial Tg assay (Beckman Access) with functional sensitivity (FS) of 0.1 ng/mL. RESULTS: The new method showed FS of 0.3 ng/mL. The correlation between the two methods was good (r = 0.74; p < 0.0001). The diagnostic sensitivity was 88.9%, and it was increased to 100% when combined with neck US. CONCLUSION: This new, high-sensitivity Tg assay presented a good correlation with Beckman Access assay and with the clinical outcome of the patients. The continuous availability of a validated assay is an additional advantage for long term follow-up of DTC patients. Arq Bras Endocrinol Metab. 2012;56(9):658-65

show abstract

Section: Introductionmentioning

confidence: 99%

Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin

Nakabashi

Biscolla

Kasamatsu

et al. 2012

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

Tc‐99m depreotide imaging of I‐131‐negative recurrent metastatic papillary thyroid carcinoma

Valsamaki

Gotzamani-Psarrakou

Tsiouris

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

The detection of radioiodine (I-131)-negative metastases of differentiated thyroid carcinoma (DTC) has been hitherto successfully tried by the well-known synthetic somatostatin analogue indium-111-labeled DTPA-octreotide (In-111 pentetreotide). The objective of this study was to evaluate the usefulness of scintiscan with the newer synthetic somatostatin analogue Tc-99m depreotide, in the restaging of papillary thyroid carcinoma (PTC) with detectable serum thyroglobulin (Tg) levels and negative I-131 whole-body scan (WBS). Whole-body planar and cervico-thoracic tomographic scintigraphy (single-photon emission tomography-SPET) with Tc-99m depreotide was performed in a 68-year-old male patient suffering from PTC stage III, with a mild increase in serum Tg levels coupled with a recent negative I-131 WBS. The findings were compared with those of neck ultrasonography (US) and computerized tomography (CT). Nodal neck dissection and histopathology provided the definitive diagnosis. Tc-99m depreotide scanning revealed foci of cervical lymph node metastases, which did not accumulate I-131. The findings were in accordance with neck US and CT. Histopathology established the diagnosis of metastatic cervical lymph node PTC. Lymph node immunoreactivity was positive for the somatostatin receptor subtypes 2, 5 and 3. Scintigraphy with Tc-99m depreotide could prove a useful adjunct to the armamentarium for the follow-up of PTC, especially in the setting of detectable serum Tg and negative I-131 WBS. ' 2006 Wiley-Liss, Inc.Key words: papillary thyroid carcinoma; metastasis; Tc-99m depreotide; I-131 whole-body scan Thyroid carcinoma (TC) is diagnosed in about 20,000 individuals in Europe each year and leads to 1,500-2,000 deaths annually. 1 It is the most frequent malignancy of the endocrine glands. However, well-differentiated TC (DTC) is a rare disease, accounting for less than 1% of all malignant neoplasms in humans. 2 The highest incidence rates are reported in countries with normal or even high dietary iodine status. The papillary subtype of DTC (PTC) comprises 60-70% of all thyroid malignancies, with a female-tomale ratio of 3:1. [2][3][4] In keeping with the literature, regional recurrence after total thyroidectomy ranges between 5 and 20% of the cases, while distant metastases develop in less than 10% and mainly involve the lungs and bones. 1 Lymph node metastases range from 35% to more than 70% in different series and are associated with higher rates of tumor recurrence. According to the 2002 TNM classification, their location, size, number and extension beyond the node capsule probably exert a prognostic impact. 1 However, recurrent PTC does not usually cause early symptoms; hence, prompt laboratory and imaging diagnostic accuracy is of the utmost importance.The determination of serum thyroglobulin (Tg) level has an established significant role in the follow-up and therapeutic decision-making of PTC after total thyroidectomy and thyroid remnant ablation with radioiodine (I-131); its detection indicates thyroid remnant, r...

show abstract

Ainda em busca do ensaio ideal para a tiroglobulina sérica no seguimento de pacientes com câncer diferenciado da tiróide

Cited by 2 publications

References 27 publications

Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin

Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin

Tc‐99m depreotide imaging of I‐131‐negative recurrent metastatic papillary thyroid carcinoma

Contact Info

Product

Resources

About